UBS Maintains Buy on Merck & Co, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

UBS analyst Michael Yee maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $130 to $145.

Comments

No comments yet. Be the first!

UBS Maintains Buy on Merck &amp; Co, Raises Price Target to $145